Using human induced pluripotent stem cell-derived liver cells to investigate the mechanisms of liver fibrosis in vitro
Biochemical Society Transactions · 2023
DOI: 10.1042/bst20221421 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Society Transactions, 2023. Verfasst von Yuta Koui und 1 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Cell Growth and Differentiation, Institute for Quantitative Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-003…. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The liver is a highly organized organ that consists of hepatic parenchymal cells, hepatocytes, and non-parenchymal cells such as the liver sinusoidal endothelial cells (LSECs), hepatic stellate cells (HSCs), cholangiocytes, and Kupffer cells. Although previous studies have primarily focused on the hepatocyte dynamics in the injured liver, recent studies have shown that non-parenchymal cells play an essential role in both liver regeneration and liver fibrosis progression. Among the non-parenchymal cells, HSCs directly contribute to the progression of liver fibrosis because the activation of HSCs in response to liver injury or inflammation results in the excess production of extra cellular matrix. LSECs also contribute to modulate the function of hepatocytes, HSCs, and immune cells during liver fibrosis. Therefore, to investigate the mechanisms for liver fibrosis in vitro, it is necessary to develop an appropriate liver model that accurately recapitulates the pathology of human liver fibrosis including HSC activation. However, the supply of human cells is limited and freshly isolated liver cells easily lose their specific characteristics in culture. To overcome this shortage of human liver cells, human induced pluripotent stem cell (hiPSC)-derived liver cells were generated by mimicking the liver developmental process. In this review article, we outline the differentiation system of liver non-parenchymal cells from hiPSCs and development of in vitro liver disease models using hiPSC-derived liver cells. We describe the utility of these liver models as experimental systems to investigate the mechanism of liver fibrosis and development of drugs for the treatment thereof.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Cell Growth and Differentiation, Institute for Quantitative Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-0032, Japan.
- Laboratory of Stem Cell and Neuro-Vascular Biology, Cell and Development Biology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, U.S.A.
ORCID-Profile: Taketomo Kido
Zitieren
APA
Koui, Y., & Kido, T. (2023). Using human induced pluripotent stem cell-derived liver cells to investigate the mechanisms of liver fibrosis in vitro. Biochemical Society Transactions. https://doi.org/10.1042/bst20221421
Vancouver
Koui Y, Kido T. Using human induced pluripotent stem cell-derived liver cells to investigate the mechanisms of liver fibrosis in vitro. Biochemical Society Transactions. 2023. doi:10.1042/bst20221421
BibTeX
@article{Koui2023,
author = {Koui, Yuta and Kido, Taketomo},
title = {Using human induced pluripotent stem cell-derived liver cells to investigate the mechanisms of liver fibrosis in vitro},
journal = {Biochemical Society Transactions},
year = {2023},
doi = {10.1042/bst20221421}
}
EUVIMED